Department of Clinical Sciences and Community Health (DISCCO)University of Milan, Milan, Italy
Laboratory of Geriatric and Oncologic Neuroendocrinology ResearchIstituto Auxologico Italiano IRCCS, Milan, Italy.
Endocr Relat Cancer. 2018 Jun;25(6):R351-R364. doi: 10.1530/ERC-18-0010. Epub 2018 Apr 11.
Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.
生长抑素类似物在神经内分泌肿瘤（NETs）的医学治疗中具有重要作用。奥曲肽和兰瑞肽都是与生长抑素受体（SSTR）2 具有高亲和力的生长抑素类似物，可控制功能性 NETs 的症状。此外，这些化合物由于其抗增殖作用，可稳定分化良好的 NETs 的生长。培高利特是一种新型的多受体靶向生长抑素类似物，对 SSTR1、2、3 和 5 具有高亲和力。本文综述了培高利特在 NETs 治疗中的最新进展，旨在探讨该分子在 NETs 管理中的临床相关性和未来前景。
